Clinical Trial Update: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant CAN-2409 with chemoradiation or SBRT for borderline resectable pancreatic adenocarcinoma; status ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Adenocarcinoma

Drugs mentioned

• CAN-2409

Snippet

Sponsor: Candel Therapeutics, Inc. | Conditions: Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING